Exploratory data suggest potential of epigenetic biomarkers in advanced UC | Joaquim Bellmunt

Joaquim Bellmunt outlines the latest analysis from the JAVELIN Bladder 100 trial pointing to a potential role for chromatin conformation loops as a biomarker of maintenance avelumab benefit in advanced urothelial cancer (3:42).
This independent video interview was supported by an educational grant from Pfizer and Merck Healthcare KGaA, Darmstadt, Germany
View more on Medicine Matters oncology: oncology.medic...